amifostine anhydrous has been researched along with ifosfamide in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bernstein, ML; Dubowy, RL; Fahey, RC; Newton, GL; Souid, AK | 1 |
| Bierings, MB; de Kraker, J; Offringa, M | 1 |
| Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A | 1 |
| Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolt, H | 1 |
| Brown, JM; Gurney, EM; Hepburn, PM; Johnson, PW; Muers, MF; Napp, VV; Peake, MD; Poulter, KM | 1 |
| Beyer, J; Dubiel, M; Hildebrandt, M; Krusch, A; Rick, O; Schleicher, J; Schwella, N; Serke, S; Siegert, W | 1 |
| Blohmer, JU; Böhmer, D; Elling, D; Ernhardt, B; Lichtenegger, W; Paepke, S; Sehouli, J | 1 |
| Berthold, F; Fichtner, I; Fulda, S; Hero, B | 1 |
| Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D | 1 |
| Beyer, J; Rick, O; Schleicher, J; Schubart, H; Schwella, N; Siegert, W | 1 |
| Springate, JE; Taub, M; Zaki, EL | 1 |
| Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML | 1 |
| Springate, J; Taub, M | 1 |
1 review(s) available for amifostine anhydrous and ifosfamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 trial(s) available for amifostine anhydrous and ifosfamide
| Article | Year |
|---|---|
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neoplasms; Child; Cyclophosphamide; Cysteine; Female; Humans; Ifosfamide; Infusions, Intravenous; Kinetics; Male; Mesna; Radiation-Protective Agents; Sarcoma, Ewing; Sulfhydryl Compounds; Time Factors | 1999 |
Lack of protection of proximal tubular cells by amifostine (ethyol) in ifosfamide-containing regimens.
Topics: Amifostine; Antineoplastic Agents, Alkylating; Child; Cytoprotection; Humans; Ifosfamide; Kidney Tubules, Proximal; Pilot Projects; Treatment Outcome | 2000 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; Kidney Diseases; Male; Middle Aged; Neoplasms | 2000 |
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Male; Middle Aged; Neoplasms | 2000 |
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2001 |
PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.
Topics: Adult; Amifostine; Antigens, CD34; Blood Specimen Collection; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Pilot Projects; Prospective Studies | 2001 |
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Division; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Humans; Ifosfamide; Mercaptoethylamines; Mice; Mice, Nude; Neuroblastoma; Neutropenia; Prodrugs; Safety; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured; Vincristine; Vomiting; Xenograft Model Antitumor Assays | 2001 |
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure | 2001 |
Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prospective Studies; Radiation-Protective Agents; Taxoids | 2001 |
5 other study(ies) available for amifostine anhydrous and ifosfamide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Glucose; Glutathione; Ifosfamide; Kidney Tubules; Mesna; Neutral Red; Rabbits | 2003 |
Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
Topics: Acrolein; Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Cystitis; Dose-Response Relationship, Drug; Edema; Glutathione; Hemorrhage; Ifosfamide; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Radiation-Protective Agents; Urinary Bladder | 2007 |
Ifosfamide toxicity in cultured proximal renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Cell Culture Techniques; Cells, Cultured; Dose-Response Relationship, Drug; Ifosfamide; Inulin; Ion Transport; Kidney Tubules, Proximal; Male; Mesna; p-Aminohippuric Acid; Protective Agents; Rabbits; Tetraethylammonium | 2007 |